Prognostic relevance of oncological serum biomarkers in liver cancer patients undergoing transarterial chemoembolization therapy (Q44357744)

2 December 2017

Prognostic relevance of oncological serum biomarkers in liver cancer patients undergoing transarterial chemoembolization therapy (English)

1 reference

2 December 2017

0 references

1 reference

Nikolaus Kohles

1

1 reference

2 December 2017

Dorothea Nagel

2

1 reference

2 December 2017

Dietrich Jüngst

3

1 reference

2 December 2017

Jürgen Durner

4

1 reference

2 December 2017

Petra Stieber

5

1 reference

2 December 2017

Stefan Holdenrieder

6

1 reference

2 December 2017

20 September 2011

1 reference

2 December 2017

1 reference

2 December 2017

33

1 reference

2 December 2017

1

1 reference

2 December 2017

33-40

1 reference

https://scigraph.springernature.com/pub.10.1007/s13277-011-0237-7

2 December 2017

0 references

cites work

Hepatocellular carcinoma in southern Germany: epidemiological and clinicopathological characteristics and risk factors

1 reference

https://api.crossref.org/works/10.1007%2FS13277-011-0237-7

Prospective analysis of risk factors for hepatocellular carcinoma in patients with liver cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-011-0237-7

Estimating the world cancer burden: Globocan 2000.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-011-0237-7

Diagnosis and Treatment of Hepatocellular Carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-011-0237-7

Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-011-0237-7

Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-011-0237-7

Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-011-0237-7

A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-011-0237-7

Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-011-0237-7

Chemoembolization for hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-011-0237-7

Imaging features of hepatocellular carcinoma after transcatheter arterial chemoembolization and radiofrequency ablation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-011-0237-7

Percutaneous image-guided therapy of intra-abdominal malignancy: imaging evaluation of treatment response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-011-0237-7

Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-011-0237-7

Nucleosomes in serum as a marker for cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-011-0237-7

Review on transarterial chemoembolization in hepatocellular carcinoma: palliative, combined, neoadjuvant, bridging, and symptomatic indications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-011-0237-7

Dysregulation of apoptosis in hepatocellular carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-011-0237-7

Cell proliferation, apoptosis and the related regulators p27, p53 expression in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-011-0237-7

Relevance of circulating nucleosomes and oncological biomarkers for predicting response to transarterial chemoembolization therapy in liver cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-011-0237-7

Circulating DNA level is negatively associated with the long-term survival of hepatocellular carcinoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-011-0237-7

Circulating deoxyribonucleic Acid as prognostic marker in non-small-cell lung cancer patients undergoing chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-011-0237-7

Factors predictive of 5-year survival after transarterial chemoembolization for inoperable hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-011-0237-7

Treatment of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-011-0237-7

A prognostic index of the survival of patients with unresectable hepatocellular carcinoma after transcatheter arterial chemoembolization

21 January 2018

1 reference

12 December 2020

Risk factors for hepatocellular carcinoma among patients with chronic liver disease

1 reference

12 December 2020

Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial. Groupe CHC

1 reference

12 December 2020

Analysis of circulating tumor DNA in plasma at diagnosis and during follow-up of lung cancer patients

1 reference

12 December 2020

Heterogeneity in the development of apoptosis in irradiated murine tumours of different histologies

1 reference

12 December 2020

Nucleosomes and CYFRA 21-1 indicate tumor response after one cycle of chemotherapy in recurrent non-small cell lung cancer

1 reference

12 December 2020

Nucleosomes, ProGRP, NSE, CYFRA 21-1, and CEA in monitoring first-line chemotherapy of small cell lung cancer

1 reference

12 December 2020

Early and specific prediction of the therapeutic efficacy in non-small cell lung cancer patients by nucleosomal DNA and cytokeratin-19 fragments

1 reference

12 December 2020

Comparison of CT findings with resected specimens after chemoembolization with iodized oil for hepatocellular carcinoma

1 reference

12 December 2020

10.1007/S13277-011-0237-7

Identifiers

DOI

1 reference

2 December 2017

1 reference